← ANALYST RATINGS · TIPRANKS
Heron Therapeutics (HRTX): analyst forecast and price target
Analyst consensus
Hold0 Buy2 Hold0 Sell
Ratings of 2 analysts in the last 3 months12-month forecast
Based on 2 price targets given in the last 3 months, the average target is —, the highest —, the lowest —. The average is — from the last price of $0.36.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $0.40 → $0.42+4.8% | Hold | +15.5% | Reiterated | 13.10.26on TipRanks 11:07 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $0.39 → $0.42+6.9% | Hold | +16.1% | Reiterated | 13.10.26on TipRanks 11:07 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $0.39 → $0.41+3.8% | Hold | +12.2% | Reiterated | 13.10.26on TipRanks 11:07 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $0.38 → $0.40+3.7% | Hold | +9.7% | Upgrade | 13.10.26on TipRanks 11:07 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $0.39 → $0.41+4.9% | Hold | +12.7% | Reiterated | 13.10.26on TipRanks 11:07 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $0.39 → $0.40+2.6% | Hold | +10.8% | Reiterated | 13.10.26on TipRanks 11:07 | — | |
| Brandon Folkes★★★★★★★★★★#10500 · hits 39% · avg −1.1% | H.C. Wainwright | — | Hold | — | Downgrade | 17.08.26on TipRanks Aug 18 05:20 | −4.3%next day −5.6% · 5 days +1.8% | ↗ |
| Serge Belanger★★★★★★★★★★#674 · hits 49% · avg +14.9% | Needham | — | Hold | — | Reiterated | 10.08.26on TipRanks 12:10 | −31.6%next day −3.3% · 5 days −4.4% | ↗ |
| Carl Byrnes★★★★★★★★★★#11765 · hits 37% · avg −4.0% | Northland Securities | $4.00 | Buy | +1,008.0% | Reiterated | 05.11.25on TipRanks 10:05 | −3.0%next day +0.2% · 5 days −0.9% | ↗ |
| Clara Dong★★★★★★★★★★#5615 · hits 50% · avg +6.6% | Jefferies | $5.00 | Buy | +1,285.0% | Reiterated | 04.11.25on TipRanks 15:55 | −2.2%next day −3.0% · 5 days +0.6% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Heron Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 6 | 4 | 2 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 1 | 1 | 4 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 10.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.03 (from $-0.03 to $-0.02). Last quarter: $-0.03.
Sales
Next quarter’s sales estimate — $38M (from $37M to $38M). Last quarter: $38M.
Best top-analyst consensus in the sector · Healthcare
About Heron Therapeutics
- CEO: Craig Alexander Collard
- Employees: 128
- 25 Fenton Main Street, Cary, NC, 27511, US
- www.herontx.com
Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform, an advanced system that enables the controlled release of various short-acting pharmacological agents. This technology ensures therapeutic concentrations are maintained for periods ranging from days to weeks following just a single administration. Among its commercialized products is SUSTOL (granisetron), an extended-release injectable designed to prevent both immediate and delayed nausea and vomiting triggered by moderately emetogenic chemotherapy, or specific anthracycline and cyclophosphamide combination therapies. Additionally, Heron markets CINVANTI, an intravenous formulation of aprepitant. CINVANTI, which acts as a substance P/neurokinin-1 receptor antagonist, is indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients undergoing highly or moderately emetogenic cancer chemotherapy. The company's development pipeline includes ZYNRELEF, an innovative dual-acting local anesthetic that combines bupivacaine, a local anesthetic, with a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam in a single fixed-dose formulation. Also in development is HTX-019, an experimental therapy aimed at preventing postoperative nausea and vomiting (PONV). Furthermore, HTX-034 is being advanced for postoperative pain management and is currently undergoing Phase Ib/II clinical trials, notably in patients recovering from bunionectomy procedures. Originally established in 1983 as A.P. Pharma, Inc., the company adopted its current name, Heron Therapeutics, Inc., in January 2014. Its corporate headquarters are situated in San Diego, California.
Data from the stock’s TipRanks forecast page, read 138 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗